Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Strategies & Market Trends : YEEHAW CANDIDATES -- Ignore unavailable to you. Want to Upgrade?

To: Galirayo who wrote (22431)	2/1/2007 5:31:02 PM
From: ~digs	Read Replies (2) \| Respond to of 23958

MGRM 1.7 - will look nice on a volume laden close over 1.8 imo Monogram Biosciences, Inc., a life sciences company, engages in the development and commercialization of molecular diagnostic products focusing on infectious diseases, cancer, and other diseases. The company's products for infectious diseases include PhenoSense HIV that directly and quantitatively measures resistance of a patient's HIV to anti-viral drugs; GeneSeq HIV for examining and evaluating the genetic sequences of a patient's HIV; PhenoSense GT; Replication Capacity HIV that measures viral fitness or the ability of a virus to reproduce and infect new cells; PhenoScreen for the identification of potential clinical drug candidates; and PhenoSense HIV Entry that measures resistance of a patient's HIV to entry inhibitors. It also offers GeneSeq HIV Entry, which examines and evaluates the genetic sequences of a patient's HIV for evidence of resistance to entry inhibitors; Co-Receptor Tropism that identifies the co-receptor the patient's virus uses to enter cells; PhenoSense and GeneSeq HIV Integrase that measures HIV resistance to integrase inhibitors for use in research and drug development; and PhenoSense HIV Antibody Neutralization for use in vaccine development programs. In addition, the company offers PhenoSense HCV and GeneSeq HCV assays for use in their drug discovery and development programs by pharmaceutical companies. Monogram Biosciences also provides eTag technology, an assay platform for analyzing very small amounts of tumor samples recovered and prepared in various methods, for use in cancer therapeutics.

To: Galirayo who wrote (22431)	2/1/2007 5:50:52 PM
From: ACAN	Respond to of 23958

Ray; [MDII] I might take a run at this one stockcharts.com